Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abiraterone. Cougar Biotechnology.

Ravi A Madan1, Philip M Arlen

  • 1National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.

Idrugs : the Investigational Drugs Journal
|December 24, 2005
PubMed
Summary

Abiraterone, an inhibitor of cytochrome P450(17alpha), is being developed for prostate cancer treatment. Early-stage clinical trials are underway to evaluate its efficacy and safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.

The oncologist·2026
Same author

Castration Resistance Accelerates Prostate Cancer Kinetics.

The Prostate·2026
Same author

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.

Frontiers in immunology·2026
Same author

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Cancer·2026

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Prostate cancer remains a significant health concern.
  • Current treatments for advanced prostate cancer have limitations.

Purpose of the Study:

  • To evaluate abiraterone, a novel cytochrome P450(17alpha) inhibitor, for prostate cancer treatment.
  • To assess the safety and preliminary efficacy of abiraterone in clinical trials.

Main Methods:

  • Abiraterone is an orally administered, selective, steroidal inhibitor.
  • Phase I clinical trials have been completed.
  • Phase I/II clinical trial designs are being finalized.

Main Results:

  • Phase I trials have been conducted.
  • Data from Phase I trials are expected to inform Phase I/II trial design.

Conclusions:

  • Abiraterone shows potential as a new therapeutic option for prostate cancer.
  • Further clinical investigation in Phase I/II trials is warranted.

Related Experiment Videos